+86-28-82633987
ISO ISO
ISO 17025 ISO 17025
usp usp
EN
CN EN

Hodgkin Lymphoma

Hodgkin Lymphoma is a type of cancer that originates in white blood cells called lymphocytes, which are part of the body's immune system. It is characterized by the presence of Reed-Sternberg cells, a distinctive type of malignant cell. This cancer typically begins in lymph nodes and can spread to other organs. Early diagnosis and advancements in treatment have significantly improved prognosis for many patients.
Catalog No Product Description CAS No. Purity Structural Formula
BP0027
15,16-Dihydrotanshinone I
15,16-Dihydrotanshinone I is an abietane diterpenoid. It has a role as an anticoronaviral agent.
87205-99-0 98% 15,16-Dihydrotanshinone I
BP1436 865-21-4 Vinblastine
BP1445 71486-22-1 Vinorelbine
BP1444 23360-92-1 Vinleurosine
BP1440
Vincristine Sulfate
Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a Ki of 85 nM. Vincristine Sulfate can cause developmental toxicity according to state or federal government labeling requirements.
2068-78-2 98% Vincristine Sulfate
BP0008
1,8-Dihydroxyanthraquinone
Chrysazin is a dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8. It has a role as an apoptosis inducer and a plant metabolite.
117-10-2 98% 1,8-Dihydroxyanthraquinone
BP1437
Vinblastine sulfate
Vinblastine Sulfate has anticancer activity, using FA-BSANPs as a drug carrier system could be effective in targeting Vinblastine Sulfate-sensitive tumors in the future. Vinblastine Sulfate could offer protection to the normal tissues against gamma-radiation-induced DNA strand breaks. The changes induced on the rabbit OM by Vinblastine sulphate are transient and that regenerative recovery leads to the restoration of the normal structure of the mucosa. Vinblastine Sulfate can cause developmental toxicity according to state or federal government labeling requirements.
143-67-9 98% Vinblastine sulfate
BP5401 244230-20-4 94% Jasnudifloside A